Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare…
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing…